Navigation Links
Mylan Announces Move to NASDAQ Stock Market
Date:12/12/2008

PITTSBURGH, Dec. 12 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that it will move its stock exchange listing to The NASDAQ Stock Market, an exchange of The NASDAQ OMX Group Inc. (Nasdaq: NDAQ), from The New York Stock Exchange (NYSE) effective Dec. 29. The company will be listed on the NASDAQ Global Select Market, and its common stock will continue to trade under the "MYL" ticker symbol.

Mylan's Vice Chairman and CEO Robert J. Coury commented: "Notwithstanding the obvious financial benefits that NASDAQ offers, the decision to switch Mylan's listing was also driven by the fact that for quite some time a greater portion of our total trading volume was already crossing on NASDAQ trading facilities. This decision, we believe, will further enhance Mylan's overall needs and efficiencies."

Mylan's mandatory convertible preferred stock and 1.25% convertible notes also will move to NASDAQ with the ticker symbols "MYLNP" and "MYLNG," respectively.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
2. Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules
3. Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately
4. Mylan Declares Quarterly Preferred Stock Dividend
5. Mylans Matrix First-to-File on Generic Version of Vfend(R) Antifungal
6. Mylan to Retain Dey, L.P., Its Specialty Pharmaceutical Subsidiary
7. Mylan to Offer $400 Million in Cash Convertible Notes
8. Mylan Creates New Womens Health Care Franchise; Signs Agreement with Famy Care to Develop and Supply 22 Oral Contraceptive Products
9. Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008
10. Mylan Declares Quarterly Preferred Stock Dividend
11. Mylan Schedules Financial Results Conference Call and Live Webcast for the Second Quarter Fiscal 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... SensorInsight ®, ... Sigfox in the U.S.A. to offer Internet of Things (IoT) solutions based ... large-scale environmental sensor deployments such as monitoring solutions used to detect potentially hazardous ...
(Date:1/17/2017)... ... January 17, 2017 , ... SC&H Group, a leading ... a Principal in its IT Advisory Services practice . Rossi is the third ... market demand for strategic IT guidance grows, and the practice continues to expand.     , ...
(Date:1/17/2017)... ... 2017 , ... Physicians Education Review®, LCC (PER®) announces philanthropist, ... the 34th Annual Miami Breast Cancer Conference®, on March 9-12, 2017 at the ... said, “We are delighted to have Sandra Lee join us as our keynote ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Many people make New Year’s resolutions or ... Robert Mondavi is making it easier for people who want to kick off 2017 ... new and existing patients. , These special offers include: , , ...
(Date:1/16/2017)... ... January 17, 2017 , ... To ... internationally recognized leader in the fast-casual category, announces a hearty and wholesome Winter ... Egg Breakfast Sandwich, Turkey Mash-Up Sandwich, Cranberry Crunch & Honey Parfait, Slow Cooked ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 17, 2017 Research and Markets has ... 2017 - 2024" report to their offering. ... This new report revisits the ... that was issued in May of 2015. Self-healing is an area ... previous analysis we projected a market potential of $2.7 billion ($US) ...
(Date:1/17/2017)... Management to Discuss Acquisition of ... KIT-302 Development On Track For An NDA ... Q1 2017   ... Holdings Ltd. (NASDAQ: KTOV ; TASE: KTOV), an innovative biopharmaceutical company, ... rd at 8:30am Eastern Time to discuss the recent acquisition of a ...
(Date:1/17/2017)... 17, 2017  Edwards Lifesciences Corporation (NYSE: ... structural heart disease and critical care monitoring, plans to ... 31, 2016 after the market closes on Wednesday, February ... 5:00 p.m. ET that day to discuss those results. ... (877) 407-8037 or (201) 689-8037.  For 72 hours following ...
Breaking Medicine Technology: